Kevin Outterson on The End of Antibiotics

In a conference earlier this summer, Professor Outterson discussed obstacles to creating new antibiotics.

Boston University Professor of Law and N. Neal Pike Scholar in Health and Disability Law Kevin Outterson, executive director of BU’s antibiotic accelerator CARB-X, joined a panel of experts to discuss his work on antibiotic resistance at PULSE: On the Front Lines of Health Care, organized by The Atlantic. Outterson discussed the obstacles in research and development as well as problems with the business model of the pharmaceutical industry that prevents the successful development of new classes of antibiotics.

View his panel, “The End of Antibiotics?” below.

Related News

• CARB-X Injects Up to $48 Million to Accelerate First Powered By CARB-X Portfolio
• Students, Alumni Shape the Future of Antibiotic Development
• CARB-X Joins United Nations’ Global Effort to Combat Antimicrobial Resistance